NasdaqGM:PTGXBiotechs
Protagonist Therapeutics Milestones Test Valuation As NDAs And Trials Advance
Protagonist Therapeutics submitted NDAs for Icotrokinra in plaque psoriasis and Rusfertide in polycythemia vera, advancing two late stage drug candidates.
The company is progressing Phase 3 trials in partnership with large pharmaceutical companies, including Johnson & Johnson and Takeda.
These filings and trial advances represent fresh milestones for NasdaqGM:PTGX that have not yet been widely discussed in the market.
Protagonist Therapeutics, trading on NasdaqGM:PTGX, is drawing fresh...